Teva Pharmaceutical Industries (TEVA) announced that the European Commission (EC) has approved its CINQAERO (reslizumab) as add-on therapy in adults patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The product will be commercially available in the coming months. It is marketed under the brand name CINQAIR in the U.S. and Canada.